Celastrol Inhibits Colorectal Cancer Through TGF-β1/Smad Signaling

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jan 23

PMID 30666129

Citations 16

Authors

Zhitao Jiang

Qianyu Cao

Guoliang Dai

Jianchun Wang

Chundi Liu

Lingyan Lv

Jinhuo Pan

Affiliations

Soon will be listed here.

Abstract

Background: There are few clinical challenges associated with the treatment of colorectal cancer (CRC). Studies have shown that TGF-β plays a crucial role in CRC. Importantly, celastrol, a major components of the root extract of the traditional Chinese herb , has been shown to inhibit the growth, adhesion, and metastasis of human CRC cells through the inhibition of TGF-β1/Smad signaling.

Materials And Methods: Real-time PCR and Western blot tests were proceeded to present TGF-β1, TGF-β receptor type I (TGFβRI), TGF-β receptor type II (TGFβRII), Smad2/3, p-Smad2/3, Smad4, and glyceraldehyde-3-phosphate dehydrogenase expression in human colon cancer cell samples.

Results: Our results indicated that celastrol can reduce the expression levels of TGF-β1, TGFβRI, and TGFβRII in HCT116 and SW620 cells. Furthermore, celastrol could also prevent the increase in Smad4 and p-Smad2/3 in HCT116 and SW620 cells.

Conclusion: Celastrol could inhibit tumor growth through TGF-β1/Smad signaling and might be a promising therapeutic component against CRC.

Citing Articles

Expression profiles and gene set enrichment analysis of the transcriptomes from the cancer tissue, white adipose tissue and paracancer tissue with colorectal cancer.

Zhang X, Zhu R, Jiao Y, Simayi H, He J, Shen Z PeerJ. 2024; 12:e17105.

PMID: 38563016 PMC: 10984182. DOI: 10.7717/peerj.17105.

Anti-angiogenesis in colorectal cancer therapy.

Yang Z, Zhang X, Bai X, Xi X, Liu W, Zhong W Cancer Sci. 2024; 115(3):734-751.

PMID: 38233340 PMC: 10921012. DOI: 10.1111/cas.16063.

TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer.

Singh S, Gouri V, Samant M Med Oncol. 2023; 40(11):335.

PMID: 37855975 DOI: 10.1007/s12032-023-02204-5.

Combination of Irinotecan and Melatonin with the Natural Compounds Wogonin and Celastrol for Colon Cancer Treatment.

Radajewska A, Moreira H, Beben D, Siwiela O, Szyjka A, Gebczak K Int J Mol Sci. 2023; 24(11).

PMID: 37298495 PMC: 10253823. DOI: 10.3390/ijms24119544.

Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action.

Chen J, Wu S, Shi Z, Hu B Chin Med. 2023; 18(1):14.

PMID: 36782251 PMC: 9923939. DOI: 10.1186/s13020-023-00719-7.

References

Bufu T, Di X, Yilin Z, Gege L, Xi C, Ling W . Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. Anticancer Drugs. 2018; 29(6):530-538. DOI: 10.1097/CAD.0000000000000621. View

Becouarn Y, Rougier P . Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. Semin Oncol. 1998; 25(2 Suppl 5):23-31. View

Fribley A, Miller J, Brownell A, Garshott D, Zeng Q, Reist T . Celastrol induces unfolded protein response-dependent cell death in head and neck cancer. Exp Cell Res. 2014; 330(2):412-422. PMC: 4280347. DOI: 10.1016/j.yexcr.2014.08.014. View

Fischer A, Jacobson K, Rose J, Zeller R . Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2011; 2008:pdb.prot4986. DOI: 10.1101/pdb.prot4986. View

Yadav V, Sung B, Prasad S, Kannappan R, Cho S, Liu M . Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med (Berl). 2010; 88(12):1243-53. PMC: 3142743. DOI: 10.1007/s00109-010-0669-3. View

Hill C . Nucleocytoplasmic shuttling of Smad proteins. Cell Res. 2008; 19(1):36-46. DOI: 10.1038/cr.2008.325. View

Biswas S, Guix M, Rinehart C, Dugger T, Chytil A, Moses H . Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest. 2007; 117(5):1305-13. PMC: 1838926. DOI: 10.1172/JCI30740. View

De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P . Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep. 2015; 34(3):1087-96. PMC: 4530899. DOI: 10.3892/or.2015.4108. View

Calixto J, Campos M, Otuki M, Santos A . Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med. 2004; 70(2):93-103. DOI: 10.1055/s-2004-815483. View

10.

Gulubova M, Manolova I, Ananiev J, Julianov A, Yovchev Y, Peeva K . Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer. Int J Colorectal Dis. 2010; 25(5):591-9. DOI: 10.1007/s00384-010-0906-9. View

11.

Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

12.

Grothey A, Sargent D, Goldberg R, Schmoll H . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7):1209-14. DOI: 10.1200/JCO.2004.11.037. View

13.

Aggarwal B, Prasad S, Sung B, Krishnan S, Guha S . Prevention and Treatment of Colorectal Cancer by Natural Agents From Mother Nature. Curr Colorectal Cancer Rep. 2013; 9(1):37-56. PMC: 3693477. DOI: 10.1007/s11888-012-0154-1. View

14.

Kang H, Lee M, Jang S . Celastrol inhibits TGF-β1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression. Biochem Biophys Res Commun. 2013; 437(4):550-6. DOI: 10.1016/j.bbrc.2013.06.113. View

15.

Picon A, Gold L, Wang J, Cohen A, Friedman E . A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomarkers Prev. 1998; 7(6):497-504. View

16.

Shaker M, Ashamallah S, Houssen M . Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. Chem Biol Interact. 2014; 210:26-33. DOI: 10.1016/j.cbi.2013.12.007. View

17.

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

18.

Massague J . TGFbeta in Cancer. Cell. 2008; 134(2):215-30. PMC: 3512574. DOI: 10.1016/j.cell.2008.07.001. View

19.

Dai G, Sun B, Gong T, Pan Z, Meng Q, Ju W . Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of colorectal cancer cells by suppressing TGF-β/Smad signaling. Phytomedicine. 2019; 56:126-135. DOI: 10.1016/j.phymed.2018.10.025. View

20.

Zhu H, Yang W, He L, Ding W, Zheng L, Liao S . Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS One. 2013; 7(12):e52333. PMC: 3527540. DOI: 10.1371/journal.pone.0052333. View